BCC

Basal Cell Carcinoma (BCC) at a Glance

BCC is the most common form of skin cancer, and the most common type of all cancers.  

 
Basal Cell Carcinoma

Affects 3.6 million people each
year in North America

Basal Cell Carcinoma

Primarily caused by 
cumulative sun exposure
 

Basal Cell Carcinoma

Most commonly develops on
sun exposed areas such as the
face, neck, and scalp 

Basal Cell Carcinoma

There remains a need for treatments
that preserve skin, minimize
discomfort, and allow patients
to return to their daily lives promptly 


BCC Subtypes and Treatments

BCCs start in basal layer of the skin and can appear in different forms depending on how they grow within the skin layers. 

Superficial BCC (≈15% of cases) 
Usually treated with topical medications, such as creams, applied directly to the skin. 

Advanced or Metastatic BCC (≈1-10% of cases) 
Treated with systemic therapies such as Hedgehog pathway inhibitors, or surgery. 

Nodular BCC (≈60-80% of cases)  
Most often treated with surgical excision. Mohs surgery, often referred as the gold standard, offers the highest precision and lower risk of recurrence. 

Skin Layers


Understanding Nodular BCC Care 

Mohs surgery is widely considered the gold-standard surgical technique for nodular basal cell carcinomas (nBCC), particularly when located in cosmetically sensitive or high-risk areas. The procedure involves removing thin layers of skin one at a time and examining each layer microscopically until no cancer cells remain.


While Mohs surgery is effective, it is a surgical procedure that can take many hours, requires preparation, may cause discomfort, and involves a recovery period. Lasting changes to the treated skin, such as scarring, discoloration, and disfigurement, can occur, and healing may take several weeks to months. For patients with multiple or recurring nodular BCCs, repeated procedures are required over time, which can become physically and emotionally demanding. Although surgery remains the primary treatment option for nodular BCC, it is not suitable for all basal cell carcinoma lesions or patients.

This underscores the need for treatments that preserve skin integrity and lead to better outcomes for patients.

 
Mohs Surgery
FLD-103 for Basal Cell Carcinoma

FLD-103: An Investigational Non-Surgical Treatment for nBCC by Feldan Therapeutics

Injected directly into nBCC tumors, FLD-103 is developed to preserve skin health and integrity while minimizing discomfort and disruption to patients' daily lives.

Our cells use different signaling systems to guide how they grow and develop. In healthy adult skin, one of these systems—called the Hedgehog pathway—is usually switched off. In basal cell carcinoma, a change in the DNA causes this pathway to become abnormally active, sending signals that drive cancer cell growth.

FLD-103 has been developed to block a key component of this pathway, helping to slow or stop the abnormal growth of cancer cells.

FLD-103 Mechanism of Action

FLD-103 Clinical Trial Status

 FLD-103 is an investigational treatment currently being evaluated in clinical trials. It is not yet approved for general use.  

*This page provides patients and families general information about these conditions, as well as insights into our innovative therapies and the ways they are developed — presented in an informative and supportive manner, while never replacing personalized medical advice.